文献类型：期刊文献

英文题名：Organoid Models for Precision Cancer Immunotherapy

作者：Sun, Cai-Ping[1];Lan, Huan-Rong[2];Fang, Xing-Liang[3];Yang, Xiao-Yun[4];Jin, Ke-Tao[5]

机构：[1]Zhejiang Univ Sch Med, Shaoxing Peoples Hosp, Shaoxing Hosp, Dept Med Oncol, Shaoxing, Peoples R China;[2]Zhejiang Univ Sch Med, Affiliated Jinhua Hosp, Dept Breast & Thyroid Surg, Jinhua, Peoples R China;[3]Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Coll Med,Dept Hepatobiliary Surg, Shaoxing, Peoples R China;[4]Zhejiang Univ, Affiliated Jinhua Hosp, Sch Med, Dept Gastroenterol, Jinhua, Peoples R China;[5]Zhejiang Univ, Affiliated Jinhua Hosp, Sch Med, Dept Colorectal Surg, Jinhua, Peoples R China

年份：2022

卷号：13

外文期刊名：FRONTIERS IN IMMUNOLOGY

收录：SCI-EXPANDED(收录号：WOS:000789349200001)、、Scopus(收录号：2-s2.0-85128542959)、WOS

基金：Funding This work was supported by National Natural Science Foundation of China (grant no. 82104445 to H-RL), Zhejiang Provincial Public Welfare Technology Application Research Project (grants no. LGF22H160046 to H-RL, and LGF21H160004 to X-LF), Jinhua Municipal Science and Technology Projects (grants no. 2021-3-040 to K-TJ, and 2021-3-046 to H-RL).

语种：英文

外文关键词：cancer; immunotherapy; organoid; precision medicine; tumor microenvironment

外文摘要：Cancer immunotherapy is exploited for the treatment of disease by modulating the immune system. Since the conventional in vivo animal and 2D in vitro models insufficiently recapitulate the complex tumor immune microenvironment (TIME) of the original tumor. In addition, due to the involvement of the immune system in cancer immunotherapy, more physiomimetic cancer models, such as patient-derived organoids (PDOs), are required to evaluate the efficacy of immunotherapy agents. On the other hand, the dynamic interactions between the neoplastic cells and non-neoplastic host components in the TIME can promote carcinogenesis, tumor metastasis, cancer progression, and drug resistance of cancer cells. Indeed, tumor organoid models can properly recapitulate the TIME by preserving endogenous stromal components including various immune cells, or by adding exogenous immune cells, cancer-associated fibroblasts (CAFs), vasculature, and other components. Therefore, organoid culture platforms could model immunotherapy responses and facilitate the immunotherapy preclinical testing. Here, we discuss the various organoid culture approaches for the modeling of TIME and the applications of complex tumor organoids in testing cancer immunotherapeutics and personalized cancer immunotherapy.